<h3>High-Level Flow</h3>
<a name="main">
<embed src="Recommendation10-flow-main.svg" width="700"/>
</a>

<h3>Sub-flow 1: Order for subacute or chronic pain?</h3>
<a href="#main">
<img src="Recommendation10-flow-sub1.svg" width="550"/>
</a>

<h3>Sub-flow 2: opioid review useful?</h3>
<a href="#main">
<img src="Recommendation10-flow-sub2.svg" width="550"/>
</a>

<h3>Sub-flow 3: drug urine screening within last 12 months</h3>
<a href="#main">
<img src="Recommendation10-flow-sub3.svg" width="550"/>
</a>
<p>
  * For guidance regarding utilizing toxicology tests for for prescribing opioids see Recommendation 10 of CDC Clinical Practice Guideline.
</p>

<h3>Sub-flow 4: possible unexpected results in urine screening</h3>
<a href="#main">
<img src="Recommendation10-flow-sub4.svg" width="550"/>
</a>
<p>
* Note on false positive and unexpected results:
<ul>
  <li>An unexpectedly negative test may be due to time since last dose, diversion, intermittent use, aberrant drug use behavior, or other factors, including a false negative result. 
Clinicians should interpret this result in the context of the overall treatment plan. </li>
  <li>Positive results may be a false positive or could represent occasional use or possible substance use disorder.</li>
  <li> For preview regarding interpreting possible false positive urine toxicology results, see http://pubmed.ncbinim.nih.gov/24986836. It is unknown if the findings reported in this article can be extrapolated to other laboratory analyzers that were not used in the referenced studies. </li>
</ul>
For guidance regarding evaluating and addressing unexpected toxicology test results, see Recommendation 10 of the 2022 CDC Clinical Practice Guideline.
</p>
